The Consequences of HIV Infection and Antiretroviral Therapy Use for Cardiovascular Disease Risk: Shifting Paradigms

Overview

Journal Curr Opin HIV AIDS

Specialty Infectious Diseases

Date 2009 Jun 18

PMID 19532047

Citations 27

Authors

Jason V Baker

W Keith Henry

James D Neaton

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: To explore the mechanisms by which HIV infection and antiretroviral therapy (ART) may increase risk for atherosclerotic cardiovascular disease (CVD), with attention to the implications of earlier initiation of ART (i.e. at higher CD4 cell counts than currently recommended by guidelines).

Recent Findings: Compared with the general population, HIV-infected patients who receive ART have a greater burden of subclinical and clinical atherosclerotic disease. Findings from a recent international treatment interruption trial (SMART) have redirected attention from ART-related drug toxicity toward a better appreciation for the consequences of untreated HIV infection, which may increase CVD risk through inflammation, upregulation of thrombotic pathways, and ultimately early vascular damage and dysfunction. In addition, CVD risk may increase with some ART, and this risk may be class-specific and/or drug-specific.

Summary: Compared with untreated HIV, ART may increase or decrease risk of CVD. Reliable data on the relative risk do not exist. A randomized trial of early ART will provide the best data for assessment of the net risks and benefits of ART use on CVD.

Citing Articles

Factors associated with late initiation of antiretroviral therapy in Iran's HIV/AIDS surveillance data.

Sharafi M, Mirahmadizadeh A, Hassanzadeh J, Seif M, Heiran A Sci Rep. 2024; 14(1):199.

PMID: 38167855 PMC: 10761711. DOI: 10.1038/s41598-023-50713-0.

Strategies of Managing Repeated Measures: Using Synthetic Random Forest to Predict HIV Viral Suppression Status Among Hospitalized Persons with HIV.

Liu J, Pan Y, Nelson M, Gooden L, Metsch L, Rodriguez A AIDS Behav. 2023; 27(9):2915-2931.

PMID: 36739589 PMC: 10403627. DOI: 10.1007/s10461-023-04015-1.

Effect of Sex on Coronary Endothelial Dysfunction in People Living With HIV.

Minhas A, Leucker T, Goerlich E, Soleimani-Fard A, Schar M, Ziogos E J Am Heart Assoc. 2022; 11(23):e026428.

PMID: 36382948 PMC: 9851436. DOI: 10.1161/JAHA.122.026428.

Assessment of cardiovascular risk factors among HIV-infected patients aged 50 years and older in Cameroon.

Tatsilong Pambou H, Gagneux-Brunon A, Fossi B, Roche F, Guyot J, Botelho-Nevers E AIMS Public Health. 2022; 9(3):490-505.

PMID: 36330283 PMC: 9581741. DOI: 10.3934/publichealth.2022034.

Factors Associated With Late Antiretroviral Therapy Initiation Among People Living With HIV in Southern Iran: A Historical Cohort Study.

Afrashteh S, Fararouei M, Ghaem H, Gheibi Z Front Public Health. 2022; 10:881069.

PMID: 35784258 PMC: 9248911. DOI: 10.3389/fpubh.2022.881069.

References

Feingold K, Krauss R, Pang M, Doerrler W, Jensen P, Grunfeld C . The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab. 1993; 76(6):1423-7. DOI: 10.1210/jcem.76.6.8501146. View

Steinberg D . Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002; 8(11):1211-7. DOI: 10.1038/nm1102-1211. View

Baliga R, Chaves A, Jing L, Ayers L, Bauer J . AIDS-related vasculopathy: evidence for oxidative and inflammatory pathways in murine and human AIDS. Am J Physiol Heart Circ Physiol. 2005; 289(4):H1373-80. DOI: 10.1152/ajpheart.00304.2005. View

Torriani F, Komarow L, Parker R, Cotter B, Currier J, Dube M . Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008; 52(7):569-76. PMC: 2603599. DOI: 10.1016/j.jacc.2008.04.049. View

Feingold K, Moser A, Shigenaga J, Patzek S, Grunfeld C . Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun. 2008; 374(2):341-4. PMC: 2571081. DOI: 10.1016/j.bbrc.2008.07.023. View

Reingold J, Wanke C, Kotler D, Lewis C, Tracy R, Heymsfield S . Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr. 2008; 48(2):142-8. PMC: 2561207. DOI: 10.1097/QAI.0b013e3181685727. View

Shankar S, Dube M, Gorski J, Klaunig J, Steinberg H . Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J. 2005; 150(5):933. DOI: 10.1016/j.ahj.2005.06.005. View

Jemsek J, Arathoon E, Arlotti M, Perez C, Sosa N, Pokrovskiy V . Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis. 2005; 42(2):273-80. DOI: 10.1086/498505. View

Shankar S, Dube M . Clinical aspects of endothelial dysfunction associated with human immunodeficiency virus infection and antiretroviral agents. Cardiovasc Toxicol. 2004; 4(3):261-9. DOI: 10.1385/ct:4:3:261. View

10.

Brenchley J, Price D, Schacker T, Asher T, Silvestri G, Rao S . Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12(12):1365-71. DOI: 10.1038/nm1511. View

11.

Mujawar Z, Rose H, Morrow M, Pushkarsky T, Dubrovsky L, Mukhamedova N . Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 2006; 4(11):e365. PMC: 1629034. DOI: 10.1371/journal.pbio.0040365. View

12.

Friis-Moller N, Reiss P, Sabin C, Weber R, Monforte A, El-Sadr W . Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007; 356(17):1723-35. DOI: 10.1056/NEJMoa062744. View

13.

Kuller L, Tracy R, Belloso W, De Wit S, Drummond F, Lane H . Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008; 5(10):e203. PMC: 2570418. DOI: 10.1371/journal.pmed.0050203. View

14.

Chironi G, Escaut L, Gariepy J, Cogny A, Teicher E, Monsuez J . Brief report: carotid intima-media thickness in heavily pretreated HIV-infected patients. J Acquir Immune Defic Syndr. 2003; 32(5):490-3. DOI: 10.1097/00126334-200304150-00004. View

15.

Sutherland J, McKinley B, Eckel R . The metabolic syndrome and inflammation. Metab Syndr Relat Disord. 2008; 2(2):82-104. DOI: 10.1089/met.2004.2.82. View

16.

Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A . HIV infection and high density lipoprotein metabolism. Atherosclerosis. 2007; 199(1):79-86. PMC: 2518204. DOI: 10.1016/j.atherosclerosis.2007.10.018. View

17.

Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P . Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation. 2001; 103(19):2323-7. DOI: 10.1161/01.cir.103.19.2323. View

18.

Blann A . Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms?. Blood Coagul Fibrinolysis. 2000; 11(7):623-30. DOI: 10.1097/00001721-200010000-00006. View

19.

Lee G, Lo J, Aweeka F, Schwarz J, Mulligan K, Schambelan M . Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis. 2006; 43(5):658-60. PMC: 3205942. DOI: 10.1086/505974. View

20.

Bozzette S, Ake C, Tam H, Phippard A, Cohen D, Scharfstein D . Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008; 47(3):338-41. DOI: 10.1097/QAI.0b013e31815e7251. View